Cyclo Therapeutics (CYTH) Institutional Ownership $0.72 0.00 (0.00%) As of 03/26/2025 Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Cyclo Therapeutics (NASDAQ:CYTH)CurrentInstitutional OwnershipPercentage68.55%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$25.10KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$75.90K Get CYTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYTH Institutional Buying and Selling by Quarter Cyclo Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025 Two Sigma Securities LLC42,541$25K0.0%N/A0.148% 2/7/2025EPIQ Capital Group LLC689,447$407K0.1%-6.8%2.396% 8/10/2024EPIQ Capital Group LLC817,270$1.04M0.4%-4.3%2.856% 2/15/2024 Founders Fund V Management LLC480,708$764K80.8%N/A2.115% 2/15/2024 Founders Fund VI Management LLC110,023$175K1.4%N/A0.484% 11/9/2021BlackRock Inc.13,134$88K0.0%+21.1%0.204% 8/16/2021 State Street Corp44,700$457K0.0%N/A0.703% 8/13/2021 Geode Capital Management LLC42,577$435K0.0%+133.2%0.670% 8/13/2021 Vanguard Group Inc.151,540$1.55M0.0%+350.4%2.383% 5/12/2021 Geode Capital Management LLC18,257$149K0.0%N/A0.287% (Data available from 1/1/2016 forward) CYTH Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYTH shares? During the previous two years, the following institutional investors and hedge funds held shares of Cyclo Therapeutics shares: Founders Fund V Management LLC ($764K), EPIQ Capital Group LLC ($407K), and Founders Fund VI Management LLC ($175K), Two Sigma Securities LLC ($25K).Learn more on CYTH's institutional investors. What percentage of Cyclo Therapeutics stock is owned by institutional investors? 68.55% of Cyclo Therapeutics stock is owned by institutional investors. Learn more on CYTH's institutional investor holdings. Which institutional investors have been buying Cyclo Therapeutics stock? The following institutional investors have purchased Cyclo Therapeutics stock in the last 24 months: Founders Fund V Management LLC ($480.71K), Founders Fund VI Management LLC ($110.02K), and Two Sigma Securities LLC ($42.54K). How much institutional buying is happening at Cyclo Therapeutics? Institutional investors have bought a total of 633,272 shares in the last 24 months. This purchase volume represents approximately $964.36K in transactions. Which Cyclo Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Cyclo Therapeutics stock in the last 24 months: EPIQ Capital Group LLC ($86.52K). How much institutional selling is happening at Cyclo Therapeutics? Institutional investors have sold a total of 86,524 shares in the last 24 months. This volume of shares sold represents approximately $75.90K in transactions. Related Companies HLVX Major Shareholders IMUX Major Shareholders CRDL Major Shareholders ZNTL Major Shareholders VXRT Major Shareholders ORMP Major Shareholders PLRX Major Shareholders TIL Major Shareholders XBIT Major Shareholders SAVA Major Shareholders This page (NASDAQ:CYTH) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTH Stock Free CYTH Stock Alerts